广州中医药大学学报2026，Vol.43Issue(1)：28-35,8.DOI:10.13359/j.cnki.gzxbtcm.2026.01.005
知柏地黄丸联合芬吗通对卵巢储备功能减退患者卵巢平均容积及卵巢颗粒细胞线粒体活性的影响
Effects of Zhibo Dihuang Pills Combined with Femoston on Mean Ovarian Volume and Mitochondrial Activity of Ovarian Granulosa Cells in Patients with Diminished Ovarian Reserve
摘要
Abstract
Objective To investigate the effects of Zhibo Dihuang Pills combined with Femoston on mean ovarian volume and mitochondrial activity of ovarian granulosa cells in patients with diminished ovarian reserve(DOR).Methods A total of 86 DOR patients with liver-kidney yin deficiency syndrome,treated in the Department of Gynecology at Taizhou Hospital of Traditional Chinese Medicine between March 2022 and September 2023,were randomized into a control group(n=43)and an observation group(n=43)using a random number table method.The control group received oral Femoston,while the observation group received additional oral administration of Zhibo Dihuang Pills.The treatment lasted for three 28-day courses.Follicular fluid reactive oxygen species(ROS)levels and mitochondrial activity of ovarian granulosa cells were measured after treatment.Changes in TCM syndrome scores,ovarian function[ovarian volume average(OVA),mean ovarian diameter(MOD),antral follicle count(AFC)],serum sex hormone levels[anti-Müllerian hormone(AMH),follicle-stimulating hormone(FSH),estradiol(E2)],and uterine artery blood flow parameters[peak systolic velocity(PSV),pulsatility index(PI),resistance index(RI)]were observed before and after treatment.Clinical efficacy and safety were evaluated.Results(1)Regarding efficacy,after three treatment courses,the total effective rate was 90.70%(39/43)in the observation group and 72.09%(31/43)in the control group.The intergroup comparison(by chi-square test)showed that the observation group demonstrated significantly superior efficacy than the control group(P＜0.05).(2)For follicular fluid ROS levels and mitochondrial activity of ovarian granulosa cells,the observation group showed significantly lower ROS levels and significantly higher mitochondrial activity than the control group after three treatment courses(P＜0.01).(3)In terms of TCM syndrome scores,both groups exhibited significant reductions in scores for menstrual abnormalities,irritability,hot flashes and sweating,insomnia with excessive dreaming,and anxiety and depression after three treatment courses(P＜0.05),with the observation group showing significantly greater reductions than the control group(P＜0.05 or P＜0.01).(4)Regarding ovarian function,both groups showed significant increases in OAV,MOD,and AFC after treatment(P＜0.05),with the observation group demonstrating significantly greater improvements than the control group(P＜0.05 or P＜0.01).(5)For sex hormone levels,both groups exhibited significant increases in serum AMH and E2 levels and a significant decrease in serum FSH levels after treatment(P＜0.05),with the observation group showing significantly greater changes than the control group(P＜0.01).(6)In terms of uterine artery blood flow parameters,both groups showed a significant increase in PSV and significant decreases in PI and RI after treatment(P＜0.05),with the observation group demonstrating significantly greater improvements than the control group(P＜0.05 or P＜0.01).(7)Regarding safety,the incidence of adverse reactions was 9.30%(4/43)in the control group and 13.95%(6/43)in the observation group,with no statistically significant difference between the groups(P＞0.05).Conclusion Zhibo Dihuang Pills combined with Femoston can effectively alleviate clinical symptoms,improve ovarian function,and enhance mitochondrial activity of ovarian granulosa cells in DOR patients with liver-kidney yin deficiency syndrome.关键词
知柏地黄丸/芬吗通/卵巢储备功能减退/肝肾阴虚型/卵巢平均容积/卵巢颗粒细胞线粒体活性/卵巢功能Key words
Zhibo Dihuang Pills/Femoston/diminished ovarian reserve/liver-kidney yin deficiency syndrome/mean ovarian volume/mitochondrial activity of ovarian granulosa cells/ovarian function分类
医药卫生引用本文复制引用
陈莉,张勤华,陈琰,顾卫华,牛凝,房彩平..知柏地黄丸联合芬吗通对卵巢储备功能减退患者卵巢平均容积及卵巢颗粒细胞线粒体活性的影响[J].广州中医药大学学报,2026,43(1):28-35,8.基金项目
国家重点研发计划项目(编号:2022YFC3500504) （编号:2022YFC3500504）
